Clinical Trial

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)

Withdrawn Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
Decision of Sponsor.
Summary
The purpose of this study is to evaluate the safety and tolerability of P-CD19CD20-ALLO1 in participants with highly active, severe, refractory SLE with or without lupus nephritis (LN). This study includes a dose-escalation stage followed by an expansion stage. It will also evaluate the cellular kinetics (CK), pharmacodynamics (PD), and efficacy of P-CD19CD20-ALLO1.
Protocol Amendment History 4 changes
critical Withdrawn before enrolling 2026-08-06
critical Trial withdrawn: Decision of Sponsor. 2026-08-06
notable Enrollment reduced: 162 -> 0 participants 2026-08-06
critical Trial status changed: Recruiting → Not Yet Recruiting 2026-04-24
Trial Details
NCT Number NCT06984341
Lead Sponsor Genentech, Inc.
Conditions Systemic Lupus Erythematosus
Start Date 2026-06-30
Primary Completion 2033-11-01 (estimated)
Study Completion 2033-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-05